SG10202011016WA - Dna antibody constructs for use against pseudomonas aeruginosa - Google Patents

Dna antibody constructs for use against pseudomonas aeruginosa

Info

Publication number
SG10202011016WA
SG10202011016WA SG10202011016WA SG10202011016WA SG10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA
Authority
SG
Singapore
Prior art keywords
pseudomonas aeruginosa
antibody constructs
use against
against pseudomonas
dna antibody
Prior art date
Application number
SG10202011016WA
Other languages
English (en)
Inventor
David Weiner
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG10202011016WA publication Critical patent/SG10202011016WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202011016WA 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa SG10202011016WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332363P 2016-05-05 2016-05-05

Publications (1)

Publication Number Publication Date
SG10202011016WA true SG10202011016WA (en) 2020-12-30

Family

ID=60203552

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809778TA SG11201809778TA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa
SG10202011016WA SG10202011016WA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201809778TA SG11201809778TA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Country Status (12)

Country Link
US (1) US20190153076A1 (fr)
EP (1) EP3452090A4 (fr)
JP (2) JP2019520085A (fr)
KR (2) KR20190025826A (fr)
CN (1) CN110072554A (fr)
AU (2) AU2017261374B2 (fr)
BR (1) BR112018072716A2 (fr)
CA (1) CA3023094A1 (fr)
EA (1) EA201892525A1 (fr)
MX (1) MX2018013525A (fr)
SG (2) SG11201809778TA (fr)
WO (1) WO2017193101A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
MX2014005566A (es) * 2011-11-07 2014-10-14 Medimmune Llc Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
EP4003333A4 (fr) * 2019-07-31 2023-11-01 The Wistar Institute for Anatomy and Biology Constructions d'anticorps d'adn multivalents et leur utilisation
WO2021022107A1 (fr) * 2019-07-31 2021-02-04 The Wistar Institute Of Anatomy And Biology Constructions d'anticorps d'adn multivalents et leur utilisation
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008333985B2 (en) * 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
RS57024B1 (sr) * 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
RU2605390C2 (ru) * 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
WO2013036914A1 (fr) * 2011-09-08 2013-03-14 University Of Florida Research Foundation, Inc. Matériaux et méthodes permettant de moduler la réponse immunitaire
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
MX2014005566A (es) * 2011-11-07 2014-10-14 Medimmune Llc Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
WO2014074528A2 (fr) * 2012-11-06 2014-05-15 Medimmune, Llc Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv
KR20150093834A (ko) * 2012-12-13 2015-08-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｄｎａ 항체 작제물 및 그 이용 방법
EP3080159A4 (fr) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Constructions d'anticorps d'adn et procédé d'utilisation
US20170183397A1 (en) * 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療

Also Published As

Publication number Publication date
AU2017261374A1 (en) 2018-12-20
SG11201809778TA (en) 2018-12-28
CN110072554A (zh) 2019-07-30
MX2018013525A (es) 2019-06-10
WO2017193101A1 (fr) 2017-11-09
BR112018072716A2 (pt) 2019-02-19
EP3452090A4 (fr) 2019-12-18
US20190153076A1 (en) 2019-05-23
KR20230093338A (ko) 2023-06-27
JP2019520085A (ja) 2019-07-18
JP2023058497A (ja) 2023-04-25
EA201892525A1 (ru) 2019-04-30
KR20190025826A (ko) 2019-03-12
AU2017261374B2 (en) 2024-06-20
CA3023094A1 (fr) 2017-11-09
EP3452090A1 (fr) 2019-03-13
AU2024203766A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
HRP20201756T8 (hr) Antitijela koja sadrže modificirane regije teškog lanca
ZA202005652B (en) Sprung coupling
EP3498840A4 (fr) Anticorps anti-lag-3
GB201601077D0 (en) Antibody molecule
HK1250737A1 (zh) 結合cd79的抗體分子
IL266143A (en) Antibody structures
GB201411420D0 (en) Antibody constructs
EP3140653A4 (fr) Analyse par immunohistochimie directe
ZA201900483B (en) Anti-cd19 antibody formulations
EP3492591A4 (fr) Anticorps anti-b7-h4
SG10202011016WA (en) Dna antibody constructs for use against pseudomonas aeruginosa
IL266857A (en) You will notice antibodies
EP3129476A4 (fr) Anticorps anti-nme
EP3601334A4 (fr) Constructions d'anticorps adn à utiliser contre le vih
EP3460343A4 (fr) Appareil de chauffage à huile
IL260083B1 (en) Antibody against myl9
GB201405856D0 (en) Functional antibody assay
EP3198065A4 (fr) Protéine de type anticorps
ZA202005650B (en) Sprung coupling
ZA202005649B (en) Sprung coupling
EP3469003A4 (fr) Anticorps anti-prl3
AU2016904779A0 (en) Antibody
EP3127922A4 (fr) Anticorps anti-sulfate de chondroïtine e